INTRODUCTION
The mammalian epidermis is a stratifi ed epithelium, one of the main functions of which is to generate a barrier, i.e. a relatively impermeable layer of dead cells, designed to protect the organism from dehydration and environmental stress. The epidermal barrier is composed of intercellular lipid lamellae with ceramides, cholesterol and fatty acids in the stratum corneum. Any barrier disruption increases transepidermal water loss TEWL and epidermal hyperproliferation, both of which are observed in abnormal skin conditions such as essential fatty acid defi ciency 1, 2 .
Gamma linolenic acid GLA: 18:3n-6 , which is metabolized from linoleic acid LA: 18:2n-6 , is known for its benefi cial effect such as improvement of lipid profi les 3 or alleviation of premenstrual syndrome PMS 4 . And GLA is also one of the most popular treatments available for dermatitis. Chung et al. investigated reversal of epidermal hyper-proliferation by GLA supplementation 5 . Brosche et al. also demonstrated that, in elderly people, consuming GLA-rich borage oil altered fatty acid metabolism and improved TEWL 6 . These and other reports strongly suggest that mal barrier function by lowering TEWL and preventing hyper-proliferation. Prostaglandin E 1 PGE 1 and 15-hydroxyeicosatrienoic acid 15-HETrE converted from GLA via di-homo-gamma linolenic acid DGLA: 20:3n-6 has anti-infl ammatory properties. On the other hand, arachidonic acid AA: 20:4n-6 is a precursor of prostaglandins PG of the 2-series such as PGE 2 and leukotriene LT B 4 which exert hyper-proliferative and infl ammatory actions 7 . 15-HETrE is a potent inhibitor of LTB 4 generation and improves skin barrier function 8 10 .
One of the anti-inflammatory factors, the alimentary availability of GLA, is in fact limited to human milk and certain herbal seeds. GLA is otherwise unavailable in ordinary foods. The oral supplementation of cretin seed oil rich in GLA, particularly evening primrose oil, results in favorable improvement in serum profi les of the intermediates of GLA. On the other hand, the fi rst hepatic step in the metabolism of LA, 6-desaturation to GLA, has been shown to be highly vulnerable to a variety of factors that may affect the condition of the skin 11 .
physiologically important fatty acids by the fermentation processes, Amano et al. found that fungi, Mucor circinelloides, accumulated GLA in a medium of up to 20 triacylglycerol 12 . To elucidate the effect of this GLA-rich oil on skin function, this mold oil was incorporated into foods and administered to 130 adults. In contrast to evening primrose oil, the mold oil is less desaturated and has good oxidation stability. In the present study, this mold oil in food was considered in connection with aromas such as that of eicosapentaenoic acid EPA , a well known anti-infl ammatory precursor.
To investigate effects of GLA supplementation, we administered GLA-containing foods to subjects with dry skin and mild atopic dermatitis AD for 12 weeks. Skin parameters, especially TEWL and water content of the epidermis were then measured. Furthermore, to confi rm the relationship between GLA and inflammation, we focused on subject groups based on levels of infl ammatory compounds, i.e. low GLA or DGLA precursor of anti-infl ammatory eicosanoids and high AA precursor of pro-infl ammatory eicosanoids .
EXPERIMENTAL PROCEDURES

Subjects
The protocol of this study was approved by the Ethics Review Board, Kensyoukai Medical Corporation Osaka, Japan , and the study was performed in accordance with the Declaration of Helsinki. The subjects were adult males and females leading healthy social lives and who responded to a recruiting advertisement for paid subjects of clinical trials by DRC Co. Ltd. Osaka, Japan and TTC Co. Ltd.
Tokyo, Japan . We selected 130 subjects with dry skin corneometer value 50 a.u. 14 and mild to moderate AD diagnosed according to the criteria of the guidelines for the treatment of AD 2009 by committee for guidelines for management of atopic dermatitis of Japanese dermatological association. Subjects with the following conditions were excluded: AD patients taking steroids, using a specific health food regularly other than the test diets, showing an allergic reaction to the test diets, being continuously treated by a physician, having severe renal dysfunction, severe liver dysfunction, severe anemia, endocrine disorders, planning pregnancy and nursing during the study period, planning to undergo anesthesia during the study period, or having any concern about developing pollinosis during the study period. Any subject judged ineligible by a physician was also excluded. The subjects recorded all foods consumed during the study period. Subjects were instructed not to diet excessively or to overeat, and excessive sunbathing was also discouraged. Six subjects with a personal reason and 2 who took other therapeutic medications anti-allergic drugs discontinued the study at the discretion of the physician. Thus, data from 112 subjects were analyzed in this study.
Test foods
Test foods were cream sandwich wafers containing the test oil or control oil. Table 1 shows the nutritional compositions of the test foods. The GLA-enriched oil test oil was extracted from the fungus Mucor circinelloides. Common blended oil, a mixture of rapeseed and soybean oils, was used as a control. The fatty acid compositions of the test and control oils were determined employing a gas chromatography system 6890 series, Agilent Technologies, CA, USA with a capillary column TC-70, GL-Science, Tokyo, Japan , after methylation with boron trifluoride 13 . The assay of the GLA content as a free fatty acid was performed using heptadecaoic acid as the internal standard. Table 2 shows the fatty acid compositions of the test and control oils. The test and control cream sandwich wafers were identical in appearance and taste.
Study design
A double-blind controlled study was performed. Before the study, the subjects were divided into two groups by an individual not directly involved in the study. The two groups were similar with respect to corneometer values and gender distributions. Another individual without Skin hydration and TEWL measurements, blood tests, urinalysis, survey of subjective symptoms and examination by a physician were performed. The subjects were fasted 6 hours before tests. Then, skin hydration and TEWL were measured, and blood and urine were collected in the fasting state on the test day.
Measurements
Measurements were taken before treatment 0 week and at 4 Tokyo, Japan . In addition, for each subject, we calculated the contents of fatty acids GLA, DGLA, AA contributing to inflammation based on plasma analysis data from 0W samples. Furthermore, for each fatty acid, we stratified based on the median for the entire subject population such that the subjects were almost equally divided. Furthermore, we divided the entire subject population into two groups, a pro-inflammatory group GLA 0.3 , DGLA 1.2 , AA 6.2
and an anti-infl ammatory group 0.3 GLA, DGLA 1.2 , AA 6.2
. For each stratification group, we performed a stratified analysis based on skin measurement data TEWL and corneometer data . 2.4.3 Subjective symptoms of itching; observation of skin symptoms As to the itching symptom, we evaluated intensity, range and frequency. We evaluated the intensity of the itching nocturnal using the visual analogue scale VAS score. No sleep disorder was given a score of 0 and I am itchy and cannot sleep at all was given a score of 100. Based on the evaluation of nocturnal itch using this score, I am itchy, and it is almost intolerable was given a score of 4, I am itchy and wake up was given a score of 3, I can sleep if I scratch was given a score of 2, I can sleep even if I do not scratch was given a score of 1, and I feel hardly any itching was given a score of 0. As to the frequency of itching, More than two days/week was given a score of 2, One day/week a score of 1 and There was no itching a score of 0.
In the observation of skin manifestations, we rated the physician s judgment of atopic state on a fi ve point scale; no symptoms was given a score of 0, mild symptoms was given a score of 1, moderate symptoms was given a score of 2, severe symptoms was given a score of 3 and more severe symptoms was given a score of 4. Desiccation, desquamation and curettage were assessed by applying a four point scale;
is a score of 0, is a score of 1, is a score of 2 and is a score of 3. Elements of papule formation were assessed on a four point scale; no symptoms is a score of 0, mild symptoms is a score of 1, moderate symptoms is a score of 2, and severe symptoms is a score of 3. Areas of eruption were evaluated on a three point scale; none is a score of 0, less than one-third of the body surface is a score of 1, one-third to two-thirds of the body surface is a score of 2 and more than two-thirds is a score of 3.
Blood test and urinalysis
Hematological tests included white blood cells WBC , red blood cells RBC , hemoglobin Hb , hematocrit Ht and platelets PLT . Biochemical tests were conducted to measure aspartate transaminase AST; GOT: glutamic oxalic transaminase , alanine transaminase ALT; GPT: glutamic-pyruvate transaminase , lactate dehydrogenase LDH , alkaline phosphatase ALP , gamma-glutamyltranserase g-GTP , total bilirubin T-Bil , albumin Alb , total protein TP , blood urea nitrogen BUN , creatinine Cre , uric acid UA , total cholesterol TC , high-density lipoprotein cholesterol HDL-C , low-density lipoprotein cholesterol LDL-C, triglycerides TG , glucose Glu , glycosylated hemoglobin HbA1c , sodium Na , potassium K and chloride Cl . Urinalysis was performed to determine specific gravity, pH, sugar, occult blood, protein, urobilinogen and ketone bodies. All of these measurements were performed by a commercial laboratory Kishimoto Clinical Laboratory Group, Tomakomai, Japan .
Statistical analysis
The measured values are presented as means standard deviation excluding values in the figures. The measured values in the figures are presented as means standard error. For comparison of TEWL, stratum corneum hydration and the VAS of itching, data obtained from the two groups before and after the test diet ingestion were employed. The unpaired or paired t-test was used for statistical comparisons. As to pruritus intensity and the frequency of subjective symptoms of itching and skin condition judgments made by physicians before and after the test diet ingestion, the Mann-Whitney U test or Wilcoxon signed-ranks test was used for comparison.
RESULTS
Characteristics of subjects
Characteristics of subjects in the efficacy and safety trials are shown in Tables 3 and 4, respectively. All mean values of height, body weight, systolic blood pressure, diastolic blood pressure and heart rate before test diet ingestion remained within normal and standard ranges. Some clinical test values were outside of reference ranges in a portion of the subjects, but they were still selected for the study after the physician judged them to be appropriate for Fig. 1 . Although no signifi cant differences were noted between the groups, TEWL of the cheek 1.47 5.25 in the control group and 3. 24 5.44 in the GLA group and forearm 0.90 3.23 in the control group and 2.03 3.77 in the GLA group tended to be lower in the GLA than the control group at week 4.
Stratum corneum hydration
Changes in stratum corneum hydration are shown in Fig.  2A cheek and 2B forearm . No significant differences were noted between the two groups.
Compositions of plasma total fatty acids
Compositions of plasma GLA, DGLA and AA before the test diet ingestion and at week 12 are shown in Table 5 . Plasma GLA was higher in the GLA than in the control group at week 12. Changes in plasma GLA and DGLA compositions in the GLA group were larger than those in the control group.
Transepidermal water loss stratifi ed data
TEWL changes in groups of subjects stratifi ed by plasma total fatty acid compositions before test diet ingestion are shown in Fig. 3 and 4 A: plasma GLA 0.3 , C: plasma DGLA 1.2 , E: plasma AA 6.2 ; the stratifi ed groups Daily GLA intake was 0.06mg in the control group and 200mg in the GLA group. 1 Values are means SD.
There were no signifi cant differences between the groups.
Fig. 1
Changes in transepidermal water loss at the cheek (A) and forearm (B) from baseline after intake of the control diet (open circles, n=61) or GLA diet (closed circles, n=61). The daily GLA intake was 0.06mg in the control group and 200mg in the GLA group. Each point represents the mean standard error. P values were obtained using the unpaired t-test for comparisons between groups.
of subjects tended to be pro-infl ammatory, B: plasma GLA 0.3 , D: plasma DGLA 1.2 , F: plasma AA 6.2 ; the stratifi ed groups of subjects tended to be anti-infl ammatory . As shown in Fig. 3C , in the stratified group of subjects whose plasma DGLA was 1.2 or less, the change in cheek TEWL of the GLA group 1.16 3.13 was significantly lower than in the control group 1.41 5.80 at week 8. The change in forearm TEWL of the GLA group 2.37 2.70 was also lower than that in the control group 0.50 3.50 at week 8 in the group of subjects stratifi ed by plasma AA over 6.2 Fig. 4E . These statistically significant differences attributable to the test diet were seen between pro-infl ammatory groups. Conversely, no statistically signifi cances or tendencies for improvement were observed between anti-inflammatory groups Fig. 3 B, D, F,  Fig. 4 B, D, F . 
Stratum corneum hydration stratifi ed data
There were no significant differences between the subject groups stratifi ed by plasma total fatty acid compositions before the test diet ingestion data not shown .
Subjective symptom of itching
There were no significant differences between the groups in the subjective symptom of diurnal itching according to the scores for VAS, pruritus intensity and frequency data not shown .
Compared with the baseline, the VAS of nocturnal itching in the GLA group was reduced i.e. improved signifi cantly at week 8. The scores for pruritus intensity and frequency of nocturnal itching were also reduced at weeks 4 and 8 in the GLA group. However, no such statistically signifi cant changes were seen in the control group during the same periods Table 6 . For all items pertaining to these subjective symptoms, there were no time points at which significant improvements were observed in the control group as compared with the GLA group.
Judgment of skin manifestations data not shown
There were no signifi cant differences between groups in the judgment of skin manifestations desiccation, desquamation, curettage, physician s judgment of atopic state, physician s judgment of itemized atopic state; erythema and acute phase papules, eczema and crusting, chronic phase papules, nodules, lichenification, area of eruption, and the sum of these items . Fig. 2 Changes in stratum corneum hydration of the cheek (A) and forearm (B) from baseline after intake of the control diet (open circles, n=61) or GLA diet (closed circles, n=61). The daily GLA intake was 0.06mg in the control group and 200mg in the GLA group. Each point represents the mean standard error. There were no significant differences between the groups. 
P<0.01 by unpaired t-test.
Signifi cantly different compared with the value before the beginning of the study, at *P<0.05 and **P<0.01 by paired t-test.
Safety trial 3.3.1 Physical measurement data not shown
Signifi cant changes were observed in physical measurement items excluding mean systolic blood pressure during the 12-week test period and the 4-week follow-up period as compared with the values of before test diet ingestion. However, all of these changes were slight and the physician judged all of them as having no clinical importance.
Adverse events data not shown
No critical or signifi cant episodes were observed and no adverse events attributable to the test diet were noted by the monitoring physician. Although some clinical test values were outside of reference ranges in a portion of the subjects, these were temporary and minor. Thus, the physician judged these changes to be minor events not related to the test substance.
Blood test and urinalysis data not shown
Although signifi cant changes were observed on hematological tests, blood biochemical tests and urinalysis after as compared with before test diet ingestion, all of the values remained within reference ranges. Hence, the monitoring physician confi rmed that there were no clinical problems related to any of these laboratory value changes.
Usage of medical agents data not shown
Eight subjects 2 healthy subjects and 6 patients with AD in the GLA group and 5 1 healthy subject and 4 patients with AD in the control group used steroids, tacrolimus or moisturizers during the test period. Steroid dosages during the test period were not changed significantly as compared with before the test diet ingestion. One subject each used tacrolimus or moisturizer and there were no major changes in the dosages of these agents. One subject used a steroid preparation as well as tacrolimus. or GLA diet (closed circles) in subjects whose composition of plasma GLA was less than 0.3% (A, GLA: n=31, Control: n=32) or above 0.3% (B, GLA: n=30, Control: n=29), plasma DGLA was 1.2% or less (C, GLA: n=27, Control: n=32) or over 1.2% (D, GLA: n=34, Control: n=29), and plasma AA was over 6.2% (E, GLA: n=31, Control: n=27) or 6.2% or less (F, GLA: n=30, Control: n=34). Participants stratifi ed by A, C and E were designated as "pro-infl ammatory", B, D and F as "anti-infl ammatory". The daily GLA intake was 0.06mg in the control group and 200mg in the GLA group. Each point represents the mean standard error. P values were obtained using the unpaired t-test for comparisons between groups.
DISCUSSION
TEWL is known to be high in skin rashes such as AD or psoriasis 15 to have lower levels of GLA and DGLA than controls and that TEWL correlated negatively with serum levels of LA metabolites such as GLA and DGLA. Consequently, it was concluded that defi ciencies in n-6 essential fatty acids correlated with the severity of skin barrier dysfunction and cutaneous infl ammation 19 .
In this study, to investigate effect of GLA supplementation, GLA-containing foods were administered to subjects with dry skin and mild AD and skin parameters, especially TEWL and water content of the epidermis were measured. After 4 weeks, the primary effi cacy analyses of skin parameters demonstrated a beneficial effect in the GLA diet group as compared with the control diet group Fig. 1 , cheek: p 0.070, forearm: p 0.077 . Although there were no signifi cant differences in other time or stratum corneum hydration indices throughout the test period, the GLA diet group showed satisfactory skin parameters low TEWL and high stratum corneum index as compared with the control diet group. Thus, our preliminary results suggest that GLA might improve skin properties and protect the skin barrier.
GLA efficiently reverses epidermal hyper-proliferation due to GLA metabolites such as anti-inflammatory eicosanoids which exert anti-proliferative properties and these actions are associated with an increase in ceramide synthesis and improvement of skin barrier function 5 . Thus, patients with high levels of pro-inflammatory eicosanoids and/or low levels of anti-infl ammatory eicosanoids appear to be more responsive to the benefi cial effects of GLA sup-
Fig. 4
Changes in transepidermal water loss at the forearm from baseline after intake of the control diet (open circles) or GLA diet (closed circles) in subjects whose composition of plasma GLA was less than 0.3% (A, GLA: n=31, Control: n=32) or above 0.3% (B, GLA: n=30, Control: n=29), plasma DGLA was 1.2% or less (C, GLA: n=27, Control: n=32) or over 1.2% (D, GLA: n=34, Control: n=29), and plasma AA was over 6.2% (E, GLA: n=31, Control: n=27) or 6.2% or less (F, GLA: n=30, Control: n=34). Participants stratifi ed by A, C and E were designated as "pro-infl ammatory", B, D and F as anti-infl ammatory. The daily GLA intake was 0.06mg in the control group and 200mg in the GLA group. Each point represents the mean standard error. P values were obtained using the unpaired t-test for comparisons between groups.
plementation.
To confi rm the relationship between GLA and infl ammatory processes, we focused on a group of subjects with proinfl ammatory features such as low levels of GLA or DGLA precursor of anti-inflammatory eicosanoids and high levels of AA precursor of pro-infl ammatory eicosanoids . As to TEWL in the pro-infl ammatory group, two signifi cant differences were seen in the GLA diet group as shown in Fig. 3C and 4E, as compared with the control group. In contrast, the anti-inflammatory group showed no significant or beneficial effects Fig. 3B, D, F, 4B , D, F . These results demonstrate the effi cacy of GLA to be very strong in subjects with high levels of pro-infl ammatory substances. Moreover, a strong relationship between the anti-infl ammatory properties of GLA and improved skin barrier function was demonstrated. Like many other reports, this study also found that GLA supplementation did not increase AA Table 5 2, 9, 10, 20, 21 .
Additionally, the Wilcoxon signed-rank test showed improvement of the pruritus score among subjective symptoms, but there was no difference between the GLA diet group and the control group Table 6 . The clinical scores showed positive and negative tendencies and were not consistent data not shown . Morse et al. reported that the effects on itching were particularly striking with GLA administration and the present results tended to be similar to theirs 22 . Most subjects in this study had dry skin but the atopic subjects had mild to moderate symptoms. These subjects were considered to have scores too low to show marked improvement. This might be why there was no pronounced propensity in the clinical fi ndings and except for the pruritus index. Although how dietary GLA effects itching is not known, pruritus markedly affects quality of life and regulation of the itch control mechanism requires further investigation. We found no significant differences at the level of the entire study population, possibly because some subjects with dry skin had conditions unrelated to fatty acid deficiency or infl ammation. For example, increased TEWL was observed in non-fi laggrin AD or sphingomyelinase impaired subjects 23, 24 . In such subjects lacking the ability to metabolize ceramides and/or fi laggrin due to genetic factors, impaired skin barrier function would not improve with only GLA supplementation and no protection from infl ammatory processes would be provided by such dietary interventions.
In this study, we focused on skin barrier function and attempted to improve the skin barrier by administration of GLA. The results obtained within 4 weeks, as demonstrated by the primary effi cacy analyses of skin parameters, confirmed a beneficial effect in the GLA diet group as compared with the control diet group. Therefore, significant differences were observed only in the group with high levels of pro-inflammatory compounds and in these subjects skin barrier function was demonstrated to be im- Values at weeks 4, 8, 12 and after the study minus the value before the beginning of the study. Signifi cantly different compared with the value before the beginning of the study, at *P<0.05 and **P<0.01 by paired t-test. Signifi cantly different compared with the value before the beginning of the study, at P<0.05 and P<0.01 by Wilcoxon signedranks test.
proved. There were no concerns regarding the safety of the cream sandwich wafers containing GLA. Although we observed very slight differences, the monitoring physician confi rmed that all items were inconsequential.
CONCLUSION
In conclusion, supplementation with GLA derived from fermentation was found to induce beneficial effects, i.e. improvement of skin barrier function, as reflected by reduced TEWL. Furthermore, statistically signifi cant efficacy was demonstrated especially in subjects with high levels of pro-infl ammatory substances. Therefore, anti-inflammatory eicosanoids delivered via GLA can enhance skin barrier function. GLA-enriched foods might safely play an important role in the skin barrier control.
